Manuka Eye Droops for Treatment of Allergy

Ocular allergy is a condition that can affect a patient's quality of life. Symptoms of ocular
allergy include but are not limited to red, itchy, swollen, foreign body sensation, watery,
puffy or blurry eyes. irritation, redness, burning, foreign body sensation, dryness, pain and
blurry vision. In many cases, ocular allergic conjunctivitis are due to seasonal allergens
like pollen, mold or indoor allergens such as pet dander or dust mites.

Ocular allergy can be treated by avoidance of known allergens, reduction of allergens by use
of HEPA filters, cleaning linens, etc, topical decongestants, over the counter and
prescription topical non-steroidals, topical or oral antihistamines, mast cell stabilizers or
topical or oral steroids.

Manuka honey is produced by bees that are associated with the flowers of the Manuka plant
(Leptospermum scoparium) that grows in New Zealand. Manuka honey is different from other
honeys because it has been shown to the more potent due to its higher methylglyoxal
concentration.

Manuka honey has been used for its anti-oxidant, anti-bacteral and anti-inflammatory
properties. It has been shown to be useful in healing eczematous skin lesions. This study
will attempt to demonstrate topical anti-allergy use for ocular allergy.

Inclusion Criteria:

1. Subject is able to read, understand and sign and informed consent.

2. Provision of signed and dated informed consent form and HIPPA authorization.

3. Stated willingness to comply with all study procedures and availability for the
duration of the study

4. Male or female, aged 10-85 years.

5. Positive bilateral CAC reaction (> or = to 2 units itching and > or = to 2 units
redness in two of three vessel beds) within 10 minutes of instillation of the last
allergen titration at visit 1 and a similarly positive bilateral CAC reaction at two
or more time points at visit 2.

6. Normal eyelid anatomy

7. BCVA of 20/100 or better in each eye and IOP 5-22 mmHg in both eyes.

8. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation and for an additional 4 weeks after the end of study drug administration

9. Are postmenopausal (no menstrual cycle for at least one year prior to Visit 1) or have
undergone bilateral tubal ligation, hysterectomy, hysterectomy with uni- or bilateral
oophorectomy, or bilateral oophorectomy.

10. Willingness to avoid the use of disallowed medications and contact lenses for the
duration of the clinical trial.

Exclusion Criteria:

1. Have a known hypersensitivity or contraindication to the investigational product or
their components.

2. Unwilling to attend study visits.

3. Active ocular disease or significant illness (clinically significant blepharitis,
uncontrolled cardiovascular disease, narrow-angle glaucoma) that could affect their
safety or the parameters of the study.

4. Contact lens use within the week prior to screening

5. Unwilling to discontinue contact lens use for the duration of the study

6. Pregnancy or lactation

7. Ocular surgery or eyelid surgery within 6 months prior to screening.

8. Subjects must be unwilling to abstain from eyelash growth products containing
prostaglandins for the duration of the trial.

9. Subjects must not have had penetrating intraocular surgery, refractive surgery or
corneal transplantation, eyelid surgery within 6 months prior to Visit 1.

10. Febrile illness within one week.

11. Treatment with another investigational drug or other intervention within one month.

12. Subjects with a history of herpetic keratitis.

13. Have serious or severe disease or uncontrolled medical condition that in the judgement
of the investigator could confound study assessments or limit compliance.

14. Use of new prescription eyedrop within 30 days of screening

15. Change in systemic medication within 30 days of screening

16. Anticipated relocation or extensive travel outside the study site that may preclude
compliance with follow up visits over the study period

17. Did not meet CAC requirements at both Visits 1 and 2.